INDGN

Indegene Limited

Strategic operating partner to global life sciences industry

Healthcare›Healthcare›Healthcare Services›Healthcare Research, Analytics & Technology

indegene.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹598.30
Market cap
14,364 Cr
Stock P/E
35.8
P/B
4.58
Dividend yield
0.3%
ROE (FY26)
12.8%
ROCE (FY26)
17.3%
Operating margin (FY26)
14.0%
OCF / EBITDA (FY26)
105.1%
OCF / EBITDA (3Y)
96.5%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Indegene sells commercial, medical, regulatory, safety and clinical operations services and AI-enabled platforms to biopharmaceutical and other life sciences companies, mostly in North America and Europe.

Company snapshot

2ndBy market cap

Ranked among 5 companies in Healthcare Research, Analytics & Technology.

Segment mix

Reportable segments as of 2024-12-31 (Consolidated). Revenue share = segment revenue ÷ total revenue.

Largest segment: 55.7% of revenue

SegmentRevenue shareRevenuePBTAssets
Enterprise Commercial Solutions
55.7%
1,162 Cr257 Cr—
Enterprise Medical Solutions
28.4%
592 Cr150 Cr—
Omnichannel Activation
12.0%
251 Cr31 Cr—
Others*
3.8%
79 Cr-23 Cr—

What we see

Positives
  • ✓96% of operating profit came in as cash over the last three years — profits are backed by real cash.
1 more signal from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricMar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales673 Cr677 Cr687 Cr720 Cr756 Cr761 Cr804 Cr942 Cr1,003 Cr1,063 Cr
Operating expenses (approx.)534 Cr548 Cr561 Cr589 Cr608 Cr606 Cr664 Cr783 Cr840 Cr889 Cr
EBITDA139 Cr129 Cr126 Cr132 Cr148 Cr155 Cr141 Cr160 Cr164 Cr174 Cr
OPM %20.6%19.1%18.4%18.3%19.5%20.4%17.5%16.9%16.3%16.4%
Other income23 Cr23 Cr21 Cr38 Cr26 Cr22 Cr20 Cr19 Cr11 Cr29 Cr
Interest12 Cr12 Cr4 Cr3 Cr3 Cr4 Cr4 Cr5 Cr7 Cr6 Cr
Depreciation19 Cr20 Cr19 Cr20 Cr21 Cr22 Cr23 Cr40 Cr42 Cr44 Cr
Profit before tax134 Cr120 Cr124 Cr146 Cr149 Cr152 Cr133 Cr135 Cr105 Cr153 Cr
Tax %29.0%26.7%26.1%25.0%21.2%23.5%23.3%23.6%24.2%23.9%
Net profit95 Cr88 Cr92 Cr110 Cr118 Cr116 Cr102 Cr103 Cr80 Cr116 Cr
EPS (₹)₹4.27₹3.79₹3.84₹4.59₹4.91₹4.86₹4.26₹4.29₹3.32₹4.84

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales966 Cr1,665 Cr2,306 Cr2,590 Cr2,839 Cr3,511 CrSign in free for the trailing twelve months
Operating expenses (approx.)736 Cr1,378 Cr1,910 Cr2,084 Cr2,305 Cr2,892 CrSign in free for the trailing twelve months
EBITDA231 Cr287 Cr396 Cr505 Cr534 Cr619 CrSign in free for the trailing twelve months
OPM %23.9%17.2%17.2%19.5%18.8%17.6%Sign in free for the trailing twelve months
Other income31 Cr26 Cr58 Cr76 Cr107 Cr72 CrSign in free for the trailing twelve months
Interest7 Cr6 Cr31 Cr49 Cr22 Cr19 CrSign in free for the trailing twelve months
Depreciation26 Cr33 Cr60 Cr76 Cr80 Cr126 CrSign in free for the trailing twelve months
Profit before tax231 Cr226 Cr363 Cr459 Cr539 Cr525 CrSign in free for the trailing twelve months
Tax %19.8%28.1%26.7%26.6%24.6%23.6%Sign in free for the trailing twelve months
Net profit149 Cr163 Cr266 Cr337 Cr407 Cr401 CrSign in free for the trailing twelve months
EPS (₹)₹7.56₹7.50₹12.03₹15.19₹17.15₹16.72Sign in free for the trailing twelve months
Dividend payout %———0.0%0.0%12.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital0.31 Cr0.35 Cr44 Cr44 Cr48 Cr48 Cr
Reserves324 Cr764 Cr1,019 Cr1,385 Cr2,568 Cr3,091 Cr
Borrowings25 Cr18 Cr394 Cr403 Cr——
Other liabilities238 Cr571 Cr746 Cr713 Cr710 Cr1,482 Cr
Total liabilities596 Cr1,353 Cr2,204 Cr2,546 Cr3,326 Cr4,620 Cr
Fixed assets (net)23 Cr34 Cr41 Cr114 Cr135 Cr194 Cr
CWIP————4 Cr12 Cr
Investments—120 Cr614 Cr797 Cr1,290 Cr1,100 Cr
Trade receivables285 Cr444 Cr642 Cr648 Cr751 Cr982 Cr
Cash & bank133 Cr506 Cr74 Cr189 Cr241 Cr301 Cr
Other assets154 Cr250 Cr834 Cr798 Cr905 Cr2,032 Cr
Total assets596 Cr1,353 Cr2,204 Cr2,546 Cr3,326 Cr4,620 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity172 Cr297 Cr130 Cr508 Cr442 Cr651 Cr
Cash from investing-24 Cr-160 Cr-893 Cr-327 Cr-683 Cr-512 Cr
Cash from financing-132 Cr233 Cr333 Cr-66 Cr288 Cr-83 Cr
Net cash flow16 Cr370 Cr-430 Cr115 Cr52 Cr60 Cr
Free cash flow (OCF − Capex)151 Cr272 Cr111 Cr497 Cr412 Cr607 Cr

Ratios

MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %66.6%29.7%27.0%27.7%21.5%17.3%
ROE %44.9%21.6%25.0%23.6%15.5%12.8%
Debtor days108971019196102
Inventory days———000
Days payable191612171219
Cash conversion cycle898190758483
OCF / EBITDA %74.6%103.5%32.9%100.5%82.7%105.1%
OCF / EBITDA % (3 years)——65.6%78.7%75.2%96.5%
Debt / equity0.080.020.370.28——
Current ratio2.302.572.962.934.482.41
Net debt / EBITDA-0.47-1.700.810.42-0.45-0.49